Form 4: CervoMed Director Hollingsworth Receives Stock Options Following Board Election

Director Jane H. Hollingsworth acquired stock options for 5,750 shares of CervoMed Inc. (CRVO) common stock on June 14, 2024, following her election to the board.

Summary

• Jane H. Hollingsworth, a director of CervoMed Inc. (CRVO), filed a Form 4 on June 14, 2024.
• The filing reports the grant of stock options to purchase 5,750 shares of CervoMed's common stock.
• The options were granted in connection with Hollingsworth's election to the Issuer's board of directors at its 2024 Annual Meeting of Stockholders.
• The exercise price of the options is $19.01 per share.
• The options vest monthly over a one-year period, starting June 30, 2024, contingent upon continued service.
• The options expire on June 14, 2034.

Sentiment

Score: 7

Explanation: The document indicates a standard director compensation practice, which is generally viewed neutrally to positively as it aligns director and shareholder interests. The sentiment is moderately positive due to the incentive structure.

Positives

• The grant of stock options aligns the director's interests with those of the shareholders.
• The vesting schedule incentivizes continued service and commitment to the company.

Future Outlook

The director's continued service is tied to the vesting of the stock options, suggesting a commitment to the company's future.

Industry Context

Stock option grants are a common form of compensation for directors, aligning their interests with shareholders and incentivizing company performance.

Comparison to Industry Standards

• Director compensation packages, including stock options, vary widely across the biotechnology industry depending on company size, stage of development, and board responsibilities.
• Comparable companies such as BioNTech, Moderna, and Novavax also utilize stock options as part of their director compensation packages.
• The specific terms of the option grants, such as vesting schedules and exercise prices, are typically benchmarked against industry peers to ensure competitiveness.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it aligns the director's interests with the company's performance.
• The director is incentivized to contribute to the company's success to realize the value of the stock options.

Key Dates